Abstract 3134
Background
Although neuroendocrine tumours (NET) constitute a very heterogeneous group, most of them express somatostatin receptors that enable treatment with somatostatin analogues, which proved to be effective both as bio- or radiopeptide therapy. However, little is now about combining these two treatment modalities. The aim of our prospective study was to evaluate the results of radiolabeled somatostatin analogues (PRRT) with or without "cold" somatostatin analogues (SA) as consolidation treatment.
Methods
Patients with well-differentiated NET treated with PRRT (4 to 5 cycles repeated every 6 to 12 weeks) were included in the study. After the last cycle of PRRT response to radiopeptide treatment was evaluated with the scintigraphic, radiological and biochemical examination. Thereafter patients were randomly assigned either to treatment with SA or observation group (2:1 randomization). Initiation of the next line of therapy was left to the discretion of treating physician. Patients were followed-up at 4-12 months intervals with radiological examinations (CT or MRI) and receptors scintigraphy. The median time to progression was measured from the start of PRRT treatment till the day of disease progression confirmed in the radiological or scintigraphic examination.
Results
125 patients (79 in SA and 46 in the observation group) were included in the study. 81 patients were randomly assigned to somatostatin analogs and 44 to the observation group. The median follow-up the calculated from the start of PRRT was 54 months for the whole group of patients. During that time 85 (68%) progressed. There was a trend to longer progression-free survival in SSA group (47 vs 44 months), however, the difference was statistically insignificant. During observation period 32 patients died and there was no difference in time to death between both groups. In 9 patients after radiopeptide therapy chemotherapy was given. Chemotherapy was well tolerated and there were no late serious side effects.
Conclusions
Preliminary results suggest that consolidation treatment with SA did not improve the results of PRRT. However, a larger number of patients and longer follow-up is necessary.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
D. Handkiewicz Junak: Travel / Accommodation / Expenses: Ipsen Novartis Genzyme-Sanofi. B. Jurecka-Lubieniecka: Travel / Accommodation / Expenses: Ipsen Novartis. B. Jarzab: Travel / Accommodation / Expenses: Ipsen Novartis Genzyme-Sanofi. All other authors have declared no conflicts of interest.
Resources from the same session
2107 - Role of Individualized Intervention(s) on Quality of Life (QOL) and Adherence to Adjuvant Endocrine Therapy in Premenopausal Women with Early-Stage Breast Cancer (BC): MyChoice Study
Presenter: Shahid Ahmed
Session: Poster Display session 2
Resources:
Abstract
5812 - Correlation between the density of tumor-infiltrating lymphocytes, immune cell subsets in tumor stroma and response to systemic therapy in breast cancer
Presenter: Cvetka Grasic Kuhar
Session: Poster Display session 2
Resources:
Abstract
4734 - BRCA1/2 Testing in HER2- Advanced Breast Cancer (ABC): Results from the European Component of a Multi-Country Real World Study
Presenter: Michael Patrick Lux
Session: Poster Display session 2
Resources:
Abstract
1686 - In vitro and in vivo rescue of resistance to BET inhibitors by targeting PLK1 in triple negative breast cancer.
Presenter: Cristina Nieto-jiménez
Session: Poster Display session 2
Resources:
Abstract
5020 - Neoadjuvant endocrine therapy in combination with melatonin and metformin in locally advanced breast cancer
Presenter: Tatiana Semiglazova
Session: Poster Display session 2
Resources:
Abstract
5082 - Melatonin and metformin in neoadjuvant chemotherapy in locally advanced breast cancer
Presenter: Tatiana Semiglazova
Session: Poster Display session 2
Resources:
Abstract
2642 - Patient-tailored tamoxifen dosing based on an increased quantitative understanding of its complex pharmacokinetics: A novel integrative modelling approach
Presenter: Anna Mueller-Schoell
Session: Poster Display session 2
Resources:
Abstract
2461 - Lack of benefit of neoadjuvant pertuzumab in high risk HER2 positive breast cancer. A retrospective case-control study of 355 cases with biomarker analysis.
Presenter: Manuela Tiako Meyo
Session: Poster Display session 2
Resources:
Abstract
4776 - Targeting CDCA3 to improve chemotherapy response in triple-negative breast cancer patients
Presenter: Kenneth O'Byrne
Session: Poster Display session 2
Resources:
Abstract
1674 - Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer
Presenter: María Del Mar Noblejas López
Session: Poster Display session 2
Resources:
Abstract